21 C.F.R. · Food and Drugs
21 C.F.R. § 60.28

Time frame for determining regulatory review periods.

Title 21 C.F.R. ● ACTIVE Primary Source
Regulatory Text

21 C.F.R. § 60.28 — Time frame for determining regulatory review periods.

§ 60.28 Time frame for determining regulatory review periods. (a) FDA will determine the regulatory review period for a product within 30 days of the receipt of a written request from PTO for such a determination and a copy of the patent term restoration application. (b) FDA may extend the 30-day period if: (1) A related FDA action that may affect the regulatory review period determination is pending; or (2) PTO requests that FDA temporarily suspend the determination process; or (3) PTO or FDA receives new information about the product that warrants an extension of the time required for the determination of the regulatory review period. (c) This section does not apply to applications withdrawn by the applicant or applications that PTO determines are ineligible for patent term restoration.

Source: ecfr.gov · govinfo.gov — public domain Official Source ↗
Root-LD Entity Data
◈ Machine-Readable Provenance Record Root-LD v1.0 · boisestandard.org
Federation ID
BS-CFR21-SEC-8CEC86
Entity Class
REGULATION / FEDERAL-CFR-SECTION
Domain Signature
boisestandard.org
Citation
21 C.F.R. § 60.28
Corpus
CFR — Code of Federal Regulations
Status
✓ ACTIVE
Source
PRIMARY-SOURCE
Source Verified
✓ TRUE
Content Hash
c22de24024e7fbc7...
Semantic Edges
Pending — corpus passes queued
The regulatory text of 21 C.F.R. § 60.28 is reproduced from the official Code of Federal Regulations as published by the Office of the Federal Register and the National Archives and Records Administration.
Navigate Corpus — Title 21 C.F.R.
◈ Provenance
boisestandard.org United States Law CFR Title 21 21 C.F.R. § 60.28